Open Access

Half of UK patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study

  • Rachel J. Black1, 2, 5Email author,
  • Rebecca M. Joseph1, 3,
  • Benjamin Brown4,
  • Mohammad Movahedi1,
  • Mark Lunt1 and
  • William G. Dixon1, 3, 4, 6
Arthritis Research & Therapy201517:375

https://doi.org/10.1186/s13075-015-0895-8

Received: 8 October 2015

Accepted: 10 December 2015

Published: 24 December 2015

Abstract

Background

Patients with rheumatoid arthritis (RA) have shared care between rheumatologists and general practitioners (GPs). Rheumatologists guide immunosuppressive therapy, whilst GPs rely on analgesia and glucocorticoid (GC) therapy to manage active disease. The objective of this study was to describe patterns of GC prescribing for patients with RA in primary care and to determine the influence of patient characteristics and prescriber.

Methods

Incident RA patients were identified within the Clinical Practice Research Datalink, a United Kingdom (UK) primary care research database. Descriptive statistics identified patterns of oral GC prescribing. Prescribers were categorised by their tendency to prescribe GCs (high/low). Logistic regression was used to identify baseline characteristics associated with GC prescriptions during follow-up and to examine whether baseline characteristics influenced prescribing differently in high versus low prescribers.

Results

A total of 7777 patients (47 %) received ≥1 GC prescription during follow-up. The average daily dose was 7.5 mg (IQR 5–15.3 mg). Of those who received GCs, >50 % were prescribed >10 mg/day and 20 % >30 mg/day. The median proportion of time spent on GCs was 26.3 % (IQR 3.8–70.0 %). Age and cardiovascular disease (CVD) were associated with increased likelihood of receiving GCs. High prescribers more commonly prescribed GC therapy in older patients and patients with hypertension.

Conclusions

Half of patients with incident RA received GCs in primary care. Average GC use was 7.5 mg for 25 % of the time, perhaps higher usage than rheumatologists and GPs might expect. GCs were prescribed more commonly in certain high-risk populations, including older patients and those with CVD.

Keywords

Glucocorticoids Rheumatoid arthritis Drug utilisation Primary care

Background

Glucocorticoid (GC) therapy was first introduced as a treatment for rheumatoid arthritis (RA) over 60 years ago [1]. GCs have potent anti-inflammatory properties that rapidly relieve joint pain, swelling and stiffness and also prevent structural damage [2]. However, they are associated with significant and predictable side effects (SEs) of concern to both patients and physicians [3, 4]. In the general population, GCs account for 2.5 % of all adverse drug reactions leading to hospital admission [5]. Guidelines for rheumatologists advocate short-term use of GCs [6], an acknowledgment that longer duration of therapy is associated with increased risk of developing certain SEs such as infection [7].

The management of RA, a condition where disease exacerbations are part of the natural history, involves shared care between the treating rheumatologist and the patient’s general practitioner (GP). Shared care for patients with RA is recommended in many international guidelines and standards of care [811] and is common practice in the UK. In early RA, GPs will often commence initial therapy, which may include simple analgesia, non-steroidal anti-inflammatory drugs (NSAIDs) and GCs. The treating rheumatologist then guides ongoing management with advice about disease-modifying anti-rheumatic drugs (DMARDs) and GC use. When faced with active disease, rheumatologists can initiate changes to DMARD therapy, however GPs rarely alter DMARDs and their options for treating disease flares that occur between rheumatology appointments are usually limited to GCs and analgesia. In some instances, GPs will initiate or continue GCs based on the recommendation of the treating rheumatologist, and on other occasions they may initiate therapy based on their own clinical judgement. The extent and pattern of GC prescribing for RA in primary care has not been well quantified or described. Therefore, it is not known if doses and duration of treatment are in keeping with current guidelines. It is important to understand if certain patient groups are more likely to receive GCs in primary care, in particular those at increased risk of developing GC SEs such as older patients or those with pre-existing comorbidities. Doctors are known to have differing beliefs about GC use and its risks [1214], therefore it is also important to understand if certain doctors prescribe more GCs.

The purpose of this study is to examine how oral GCs are prescribed for patients with RA in UK primary care. The primary objective is to describe overall drug utilisation and patterns of dose and duration. Secondary objectives are to explore the association between patient characteristics and GC use, and to examine variability in prescribing practices between prescribers.

Method

Data source

This study utilised the Clinical Practice Research Datalink (CPRD) [15], an automated database that contains pseudonymised, prospectively collected electronic medical records from registered UK general practices. In the UK, healthcare is centralised through GPs and electronic medical records are maintained and updated within general practices. The electronic medical records contain all primary care details plus information about referrals. Anonymised prescriber and practice codes are also available as part of the CPRD dataset.

Studies have found the data held by the CPRD to be representative of the UK population in terms of age and gender structure [16, 17]. Validation studies have demonstrated good completeness and accuracy of the data, particularly for chronic diseases [18, 19]. The CPRD has its own internal quality measures at the patient and practice level, including acceptability flags based on contiguity and quality of patient data, and an ‘up to standard’ date for practices based on continuity of data recording [20]. UK primary care electronic medical records use a unique coding system with Read codes assigned to medical diagnoses and Product codes assigned to medications [21].

Population and follow-up period

Figure 1 outlines how the cohort of incident RA was derived. All patients with an RA code recorded in CPRD between 1 January 1992 and 31 December 2009 were identified. A validated algorithm, shown to have a sensitivity of 84 % and a specificity of 86 % when compared to the American College of Rheumatology 1987 revised RA classification criteria [22], was then used to identify patients with true RA. The RA diagnosis date was defined as the date of the first RA code in patients with validated RA. Patients with incident RA were identified as those with an RA diagnosis date on or after the 1 January 1992 and at least 12 months of data recorded prior to diagnosis. Those with a GC prescription greater than a pre-defined maximum prednisolone equivalent dose of 100 mg per day and those aged less than 16 years were excluded. Follow-up began on the date of RA diagnosis and ended when the patient left the practice, died, the study period finished (31 December 2009) or on the date data was last collected from the practice, whichever occurred first.
Fig. 1

Steps taken to obtain the final cohort

Table 1

Patient characteristics thought to be potentially relevant to GC prescribing practices

Patient demographics

Age

Gender

GC-associated comorbidities

Musculoskeletal

Osteoporosis, avascular necrosis, myopathy

Endocrine/metabolic

Diabetes

Cardiovascular

Hypertension, hyperlipidaemia, cardiovascular diseases (myocardial infarction, angina, stroke)

Gastrointestinal

Peptic ulcer disease, pancreatitis

Psychological/behavioural

Depression, psychosis, insomnia

Inflammatory comorbidities

Respiratory

Chronic obstructive pulmonary disease, asthma, lower respiratory tract infections

Skin diseases

Atopic eczema, cutaneous vasculitis, cutaneous lupus

Gastrointestinal diseases

Inflammatory bowel disease (ulcerative colitis, Crohn’s disease)

DMARDs

Methotrexate

 

Sulfasalazine

 

Hydroxychloroquine

 

Leflunomide

 

Other DMARDs

Cyclosporine, azathioprine, penicillamine, chloroquine, gold

GC glucocorticoid, DMARDs disease-modifying anti-rheumatic drugs

Outcome measure: glucocorticoid prescriptions

All prescriptions of oral GCs (prednisolone, cortisone, hydrocortisone, triamcinolone, methylprednisolone, dexamethasone, bethamethasone, budesonide and deflazacort) were identified. Dosages were converted to a prednisolone-equivalent daily dose. Patients were classified as having ever or never been prescribed oral GCs according to receipt of at least one prescription during their follow-up period.

Predictors: patient characteristics and prescriber tendency

Baseline patient characteristics postulated to potentially influence prescribing were divided into demographics, other inflammatory indications for GCs, GC-associated comorbidities (e.g. osteoporosis, diabetes) and DMARD use as a surrogate for disease severity (Table 1). Characteristics and DMARDs were defined as being present at baseline if the diagnosis date or first prescription date occurred on or before RA diagnosis date.

The primary (i.e. most frequent) prescriber of all medications was determined for each patient. For each primary prescriber, the mean proportion of time their patients spent on GCs during follow-up was calculated by dividing the length of time spent on GCs by the length of follow-up time for each patient and then determining the mean of this value amongst all patients seen by a given primary prescriber. Prescriber tendency was then assigned as ‘high’ or ‘low’ prescribers based on whether the mean proportion of time their patients spent on GCs was above or below the median value.

Statistical analysis

Descriptive analysis

Descriptive statistics were used to identify patterns of GC prescribing including: ever use (yes/no), dose, duration and then dose and duration combined. Ever use was determined as a binary yes/no variable for the observation period and separately for the 12 months prior to diagnosis. For patients who received at least one GC prescription during the observation period, the average, lowest and highest prednisolone equivalent daily doses were determined for the time they were exposed. The median of these values across all treated patients was then calculated as a population summary statistic. The proportion of patients to ever receive greater than 5 mg, 10 mg, 20 mg and 30 mg per day was also determined.

The total number of patient years contributing to the follow-up period was determined, as was the number of patient years spent on and off GCs. For each patient that ever received GCs, the duration of follow-up, duration on GCs and proportion of their total follow-up time spent on GCs was determined. The median of these values was calculated as a population summary statistic.

A GC course was defined as consecutive GC prescriptions where the end date of the first prescription was not more than one calendar day different from the start date of the next prescription. The median number of courses per year and the number of patients with a single course longer than 3 months and 1 year was determined. Finally, dose and duration were combined and the proportion of patients taking more than 5 mg/day and 10 mg/day for greater than 3 months and 1 year was calculated.

The number of patients receiving a GC injection and the median number of injections per patient was also determined.

Patient characteristics

Univariate logistic regression, adjusted for age and gender, was initially carried out and then stepwise logistic regression was used to identify baseline patient characteristics associated with GC prescriptions (ever versus never) including demographics, other possible inflammatory indications, GC-associated comorbidities and DMARDs.

Prescriber tendency

Univariate logistic regression with an interaction term was used to determine the effect of prescriber tendency on the likelihood of receiving a GC prescription (ever versus never) during follow-up and to test the interaction between prescriber tendency and baseline patient characteristics, including patient demographics and GC-associated comorbidities.

All analyses were carried out using Stata version 12.1 (StataCorp LP, College Station, TX, USA). The study was approved by the CPRD Independent Scientific Advisory Committee (protocol 11_113RA2).

Results

From 1 January 1992 to 31 December 2009, 60,186 patients had at least one code for RA. Once the validated algorithm was applied to this cohort, 38,884 RA patients from 636 general practices across the UK were identified. Of these, 4856 were excluded because their RA diagnosis date occurred after their end of follow-up date, 12 were excluded due to a prednisolone-equivalent daily dose greater than a pre-defined maximum of 100 mg per day and 139 were excluded because they were aged less than 16 years. A total of 16,536 remained in the final cohort after the definition for incident RA was applied as shown in Fig. 1. The majority of the patients were female (69.3 %) and the median age was 59.8 years [interquartile range (IQR) 49.0–70.3].

Patterns of GC use

Ever use (yes/no)

There were 7777 (47 %) patients who received at least one oral GC prescription during the study period and these patients were classified as ever receiving a GC prescription. There were 3412 patients (20.6 %) who received a GC prescription in the 12 months preceding their diagnosis. Of these, 2940 (86.2 %) were prescribed further GCs during the follow-up period.

Dose

For those that ever received GCs, the population distribution was a median of 7.5 mg per day (IQR 5–15.3 mg) for the average dose, 5 mg per day (IQR 2.5–7.5 mg) for the lowest dose and 15 mg per day (IQR 7.5–30 mg) for the highest dose. Of those prescribed GCs during follow-up, 83 % ever received a prednisolone equivalent daily dose of more than 5 mg/day, 58 % more than 10 mg/day, 39 % more than 20 mg/day and 18 % more than 30 mg/day.

Duration of GC therapy

Total follow-up time was 92,641 patient years (mean 5.6 years/patient), with 14,382 (15.5 %) patient years spent on GCs and 78,259 (84.5 %) patient years spent off GCs. Of the 7777 patients who received GCs during follow-up, the median duration of follow-up time spent on GCs was 0.80 years (IQR 0.15–2.56) and the proportion of time spent on GCs was 26.3 % (IQR 3.8–70.0 %).

Of those who received GCs in the 12 months prior to diagnosis, the median proportion of time spent on GCs during that year was 22.7 % (IQR 5.4–67.2 %). Table 2 summarises GC doses and duration of use.
Table 2

Summary statistics of GC doses and duration of use per patient during follow-up and in the 12 months prior to study entry for those patients ever prescribed GCs (n = 7777)

 

Follow-up period

12 months prior to study entry

Measure*

Median

IQR

Median

IQR

Duration of follow-up (years)

5.29

2.62–8.58

-

-

Cumulative duration of GC use (years)

0.80

0.15–2.56

0.23

0.05–0.67

Proportion of follow-up time on GCs (%)

26.3

3.8–70.0

22.7

5.4–67.2

Average dose** (mg)

7.5

5–15.3

10

5–20

Lowest dose** (mg)

5

2.5–7.5

5

3–15

Highest dose** (mg)

15

7.5–30

15

6–30

GC glucocorticoid, IQR interquartile range

*Summary statistics were obtained by calculating the value for each patient and then determining median values across the whole population

**All doses are prednisolone-equivalent daily doses

Of those that received GCs, the median number of GC courses throughout follow-up was 5 (IQR 2–12) and the median number of courses per year was 1.4 (IQR 0.4–3.0). The number of patients that received more than two GC courses per year was 3060 (39.3 % of those that received GCs). The median duration of each GC course was 50 days (IQR 21–111). Of those that received GCs, 57.1 % received a course longer than 3 months and 13.1 % were prescribed a GC course lasting longer than 1 year.

Dose and duration of treatment

Of those prescribed GCs, 26.6 % received continuous treatment with more than 5 mg/day for longer than 3 months and 2.4 % received continuous treatment with greater than 5 mg/day for longer than 1 year. 4.7 % received more than 10 mg/d for more than 3 consecutive months.

GC injections

There were 8373 prescriptions for GC injections (intramuscular, intra-articular and periarticular) during the study period in 2911 patients (37 % total cohort). The majority were for methylprednisolone (72 %), followed by triamcinalone (21 %), prednisolone (4 %) and hydrocortisone (3 %). The median number of injections per patient was 2 (IQR 1–3).

Patient factors associated with GC prescribing

Each 10-year increase in age was associated with a 17 % greater likelihood of being prescribed GCs [odds ratio (OR), 1.17 95 % confidence interval (CI) 1.14–1.20]. Higher GC prescribing was seen in patients with inflammatory comorbidities of the lung: asthma (OR 1.58, 95 % CI 1.42–1.76), chronic obstructive pulmonary disease (OR 1.63, 95 % CI 1.33–1.99) and lower respiratory tract infections (OR 1.22, 95 % CI 1.11–1.34). However, there was no association with inflammatory conditions of the skin or gastrointestinal tract (GI) tract (Table 3).
Table 3

Baseline patient characteristics associated with GC prescriptions

Variable

Ever GC use (number, %)

Never GC use (number, %)

Univariate analysis* (odds ratio, 95 % CI)

Multivariate stepwise analysis (odds ratio, 95 % CI)

Baseline demographics

 

Age (decades)

  

1.02, 1.02–1.02**

1.17, 1.14–1.20

Gender (female)

5313, 68.32 %

6153, 70.25 %

0.94, 0.88–1.00

 

Current smoking (versus never)

2147, 27.61 %

2385, 27.23 %

1.04, 1.00–1.08**

1.22, 1.13–1.32

Baseline GC-associated comorbidities

 

Osteoporosis

427, 5.49 %

279, 3.19 %

1.42, 1.21–1.66**

 

Avascular necrosis

7, 0.09 %

4, 0.05 %

1.68, 0.49–5.78

 

Myopathy

14, 0.18 %

10, 0.11 %

1.35, 0.60–3.08

 

Diabetes mellitus

603, 7.75 %

699, 7.98 %

0.85, 0.76–0.95**

0.71, 0.62–0.82

Cardiovascular disease

364, 4.68 %

264, 3.01 %

1.22, 1.04–1.44**

1.25, 1.03–1.51

Hypertension

1842, 23.69 %

1754, 20.03 %

0.98, 0.90–1.06

 

Hyperlipidaemia

798, 10.26 %

830, 9.48 %

0.93, 0.84–1.04

0.86, 0.76–0.97

Peptic ulcer disease

382, 4.91 %

334, 3.81 %

1.13, 0.97–1.32

 

Pancreatitis

46, 0.59 %

43, 0.49 %

1.11, 0.73–1.70

 

Depression

1684, 21.65 %

1847, 21.09 %

1.11, 1.03–1.19 **

 

Insomnia

985, 12.67 %

865, 9.88 %

1.21, 1.10–1.34**

 

Psychosis

56, 0.72 %

52, 0.59 %

1.24, 0.84–1.81

 

Baseline inflammatory comorbidities

 

Chronic obstructive pulmonary disease

540, 6.94 %

189, 2.16 %

2.74, 2.31–3.25**

1.63, 1.33–1.99

Asthma

1492, 19.18 %

925, 10.56 %

2.07, 1.89–2.27**

1.58, 1.42–1.76

Lower respiratory tract infection

1717, 22.08 %

1342, 15.44 %

1.47, 1.35–1.59**

1.22, 1.11–1.34

Inflammatory bowel disease

78, 1.11 %

63, 0.72 %

1.35, 0.96–1.89

 

Cutaneous lupus

13, 0.17 %

11, 0.13 %

1.30, 0.58–2.93

 

Cutaneous vasculitis

6, 0.08 %

0, 0.00 %

1

 

Atopic eczema

1084, 13.94 %

1127, 12.87 %

1.10, 1.00–1.20**

 

Baseline DMARD use

 

Methotrexate

465, 5.98 %

501, 5.72 %

1.07, 0.93–1.22

0.80, 0.66–0.97

Sulfasalazine

468, 6.02 %

581, 6.63 %

0.91, 0.80–1.03

0.69, 0.58–0.83

Hydroxychloroquine

259, 3.33 %

256, 2.92 %

1.20, 1.00–1.43**

 

Leflunomide

105, 1.35 %

71, 0.81 %

1.83, 1.35–2.49**

1.75, 1.18–2.59

Other DMARDs***

277, 3.56 %

151, 1.72 %

2.06, 1.68–2.52**

1.68, 1.28–2.19

GC glucocorticoid, DMARDs disease-modifying anti-rheumatic drugs, CI confidence interval

*Adjusted for age and gender

**Significant in univariate analysis

***Other DMARDs include gold, penicillamine, cyclosporine, chloroquine and azathioprine

The association with pre-existing comorbidities known to be associated with GC therapy was less consistent. GC prescribing was higher in patients with pre-existing cardiovascular disease (CVD) (OR 1.25, 95 % CI 1.03–1.51) and in current smokers (OR 1.22, 95 % CI 1.13–1.32) but lower in patients with diabetes mellitus (DM) (OR 0.71, 95 % CI 0.62–0.82) and high cholesterol (OR 0.86, 95 % CI 0.76–0.97). There was an association with osteoporosis, depression and insomnia seen in the univariate model, but these factors were not included in the final multivariate model. There was no significant association with other GC-associated comorbidities at baseline including avascular necrosis, myopathy, hypertension (HTN), peptic ulcer disease (PUD) or pancreatitis.

A previous GC prescription prior to RA diagnosis was the strongest predictor of ever receiving a prescription post-diagnosis (OR 9.50, 95 % CI 8.51–10.60). GC prescribing was lower with baseline methotrexate and sulfasalazine use, but higher with leflunomide and ‘other’ DMARD use.

Prescriber tendency and GC prescribing

In total 3270 GPs were assigned as primary prescribers. The mean proportion of time their patients spent on GCs ranged from 0 to 100 % (median 11.3 %, IQR 0.11–25.9 %). GPs were thus categorised as ‘high’ prescribers if their patients spent a mean of ≥11.3 % of follow-up on GCs. A total of 6427 (38.9 %) patients were assigned a ‘low’ GC prescriber and 10,109 (61.1 %) were assigned a ‘high’ GC prescriber.

By definition, the likelihood of a patient receiving a GC prescription during follow-up was greater if they were seen by a ‘high’ GC prescriber compared to a ‘low’ GC prescriber (OR 3.10, 95 % CI 2.90–3.31). The probability of receiving a GC prescription increased with each decade of patient age for both ‘low’ (OR 1.15, 95 % CI 1.11–1.20) and ‘high’ (OR 1.26, 95 % CI 1.23–1.29) prescriber groups (Table 4). This effect differed significantly between the two prescriber groups (p <0.001), suggesting that although all older patients were more likely to receive GCs, the effect of age was greater in those seen by a ‘high’ prescriber. In other words, high prescribers were even more likely to prescribe GCs in elderly patients.
Table 4

Effect of baseline characteristics on GC prescriptions according to prescriber tendency

Variable

Low prescriber group (OR, 95 % CI)

High prescriber group (OR, 95 % CI)

p value**

Demographics

   

Age (decades)

1.15, 1.11–1.20*

1.26, 1.23–1.29*

<0.001

Gender (female)

0.98, 0.87–1.10

0.89, 0.82–0.97*

0.211

Current smoker (versus never)

1.09, 1.02–1.17*

1.07, 1.02–1.13*

0.744

GC-associated comorbidities

   

Osteoporosis

1.49, 1.14–1.95*

1.84, 1.50–2.25*

0.225

Avascular necrosis

2.28, 0.32–16.22

1.84, 0.36–9.51

0.870

Myopathy

2.29, 0.57–9.15

1.23, 0.45–3.38

0.479

Diabetes mellitus

0.88, 0.72–1.08

1.02, 0.88–1.18

0.257

Cardiovascular disease

1.38, 1.04–1.84*

1.62, 1.31–2.00*

0.373

Hypertension

1.08, 0.95–1.24

1.29, 1.17–1.41*

0.039

Hyperlipidaemia

1.10, 0.92–1.31

1.07, 0.94–1.22

0.829

Peptic ulcer disease

1.36, 1.06–1.74*

1.33, 1.09–1.63*

0.910

Pancreatitis

1.00, 0.49–2.05

1.44, 0.81–2.54

0.442

Depression

1.09, 0.96–1.23

1.09, 0.99–1.20

0.994

Insomnia

1.27, 1.08–1.50*

1.36, 1.20–1.54*

0.548

Psychosis

1.14, 0.60–2.17

1.29, 0.78–2.14

0.767

Prior use

   

GC prescription prior to follow up

6.52, 5.51–7.71*

11.76, 10.24–13.51*

<0.001

GC glucocorticoid, OR odds ratio, CI confidence interval

*Significant predictors of GC prescriptions (unadjusted)

** p value indicates significance of any differing effect between high and low prescriber groups

It was hypothesised that those with a greater tendency to prescribe GCs may be prescribing inappropriately to those with baseline GC-associated comorbidities. This was only seen for prescribers whose patients had a baseline diagnosis of HTN, who were more likely to receive a GC prescription in the ’high’ prescriber group (OR 1.29 95 % CI 1.17–1.42), but not in the ‘low’ prescriber group (OR 1.08 95 % CI 0.95–1.24), with the effect differing significantly between groups (p = 0.039).

Discussion

This study set out to describe the utilisation of GC therapy for RA in primary care, patterns of GC prescribing and to examine the influence of patient factors and prescriber tendency on GC prescribing amongst GPs for patients with RA. Nearly half the cohort received a GC prescription in primary care during follow-up, consistent with the findings of the QUEST-RA study [23]. The population distribution of the mean prednisolone-equivalent daily dose was 7.5 mg, taken for around 25 % of follow-up time in GC users. This average dose of 7.5 mg is within the European League Against Rheumatism (EULAR) definition of low-dose therapy of ≤7.5 mg per day [24], and in keeping with studies reporting efficacy [2528] and reduced adverse effects with low-dose therapy[4]. However, more than 50 % were prescribed doses >10 mg per day at some point and nearly 20 % were prescribed doses greater than 30 mg per day. The indication for prescriptions is not available in CPRD, therefore it is difficult to know whether high-dose steroids were prescribed for the patient’s RA or for other indications. The median cumulative duration of time spent taking GCs was 0.8 years/10 months with the interquartile range spanning from 0.15 years/2 months to 2.56 years. This highlights that some patients are taking GCs for longer than recommended [29], placing them at increased risk of developing SEs [30, 31].

As expected, the presence of certain inflammatory comorbidities at diagnosis, in particular inflammatory lung conditions, influenced GC prescribing. Of concern, GC therapy was prescribed more commonly in certain higher risk populations, including older patients and those with CVD. These findings are in keeping with a recent prospective RA study that found rheumatologists were more likely to prescribe GCs and less likely to commence DMARDs in patients who develop RA at an older age, who were also more likely to have comorbidities including CVD, HTN and DM [32]. The authors postulated that this might be due to clinician concerns about the potential side effects of DMARDs in older patients, particularly those with more comorbidities. However, they also point out that DMARDs are well tolerated in older patients [33] compared to the potential difficulties of GC SEs in older patients. It has been shown that RA patients taking ≥7.5 mg prednisolone per day are at increased risk of CVD [34, 35]. Pre-existing CVD, HTN and smoking, an important risk factor for CVD, may worsen cardiovascular outcomes further. Although patients with baseline DM and hyperlipidaemia received fewer GC prescriptions, it was also concerning that other baseline conditions such as PUD had no influence on GC prescribing.

Baseline use of methotrexate and sulfasalazine was associated with less GC prescribing and is in keeping with the knowledge that early treatment of RA within the ‘window of opportunity’ leads to lower disease activity [36], and potentially reduced GC requirement. Several studies have suggested that GC prescribing is also influenced by biological DMARDs (bDMARDs), which have been shown to have a GC-sparing effect [3740]. In the UK, bDMARDS can only be prescribed by rheumatologists and this data is therefore not captured by CPRD. Therefore this study was unable to assess the influence of these agents on GC prescribing.

The strengths of this study include the large cohort size and the real-life setting in which CPRD data is captured. All oral GC prescriptions were recorded within the database, meaning there was no missing prescription data. The main limitation of this study design was the lack of access to measures of disease activity, which would be expected to be important in understanding which patients receive GC prescriptions. The information needed for standard measures of disease activity such as EULAR response and disease activity score (28-joint count) (DAS28) are not routinely collected by GPs and were therefore not available on the CPRD database. A second limitation of this study is that it was unable to assess the influence of rheumatologist prescribing practices or advice on GC prescribing in primary care as rheumatologist prescribing data is not captured in CPRD. However, it is likely that some GC prescriptions will be initiated by a rheumatologist and continued in primary care. On other occasions, GPs may initiate GCs knowing that this is the practice/recommendation of the treating rheumatologist when faced with active disease. This interaction between prescribers is of interest and warrants further investigation in the future.

Conclusions

In conclusion, this study has found that 50 % of patients with incident RA were prescribed GCs in UK primary care for 25 % of the time they were observed. Of those who received GCs, more than 50 % were prescribed doses >10 mg per day and nearly 20 % were prescribed doses greater than 30 mg per day. Many GPs and rheumatologists may be surprised by the proportion of patients, the dosages prescribed and the duration of use of GCs in primary care, highlighting the need to be aware of GC use in this setting in order to avoid excess exposure and associated side effects. Certain baseline comorbidities influenced GC prescribing, including some high-risk patient groups that were more likely to receive GC prescriptions. This information is useful for both rheumatologists and GPs involved in the care of patients with RA because it highlights the extent of GC prescribing in primary care and identifies at risk groups more likely to receive GCs. Given the variety of treatment options available for RA, it is important to consider the individual patient’s specific comorbidities and risk of developing GC SEs and introduce alternative therapies where appropriate.

Abbreviations

bDMARDs: 

biological disease-modifying anti-rheumatic drugs

CI: 

confidence interval

CPRD: 

Clinical Practice Research Datalink

CVD: 

cardiovascular diseases

DAS28: 

disease activity score (28-joint count)

DM: 

diabetes mellitus

DMARDs: 

disease-modifying anti-rheumatic drugs

EULAR: 

European League Against Rheumatism

GC: 

glucocorticoid

GP: 

general practitioner

HTN: 

hypertension

IQR: 

interquartile range

NSAIDs: 

non-steroidal anti-inflammatory drugs

OR: 

odds ratio

PUD: 

peptic ulcer disease

RA: 

rheumatoid arthritis

SE: 

side effect

UK: 

United Kingdom

Declarations

Acknowledgments

RJB was the recipient of the 2013 Ken Muirden Overseas Training Fellowship, an educational research grant jointly funded by Arthritis Australia and Roche Products Pty Ltd.

RMJ was funded by the NIHR Manchester Musculoskeletal Biomedical Research Unit. WGD and MM were supported by a Medical Research Council Clinician Scientist Fellowship (G0902272). We thank the Arthritis Research UK for their support: Arthritis Research UK grant number 20380. This report includes independent research supported by (or funded by) the National Institute for Health Research Biomedical Research Unit Funding Scheme. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute for Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester
(2)
Department of Medicine, The University of Adelaide
(3)
NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre
(4)
Health e-Research Centre, Farr Institute for Health Informatics Research, Manchester Academic Health Science Centre, The University of Manchester
(5)
Department of Rheumatology, The Basil Hetzel Institute for Translational Health Research
(6)
Department of Rheumatology, Salford Royal NHS Foundation Trust

References

  1. Hench PS, Kendall EC, Slocumb CH, Polley HF. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions - a study in clinical physiology. Arch Intern Med. 1950;85:545–666.View ArticleGoogle Scholar
  2. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev. 2007;1:CD006356.PubMedGoogle Scholar
  3. Nassar K, Janani S, Roux C, Rachidi W, Etaouil N, Mkinsi O. Long-term systemic glucocorticoid therapy: patients’ representations, prescribers’ perceptions, and treatment adherence. Joint Bone Spine. 2014;81:64–8.PubMedView ArticleGoogle Scholar
  4. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Ines LB, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285–93.PubMedPubMed CentralView ArticleGoogle Scholar
  5. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–9.PubMedPubMed CentralView ArticleGoogle Scholar
  6. National Institute of Health and Clinical Excellence. NICE clinical guideline 79. Rheumatoid arthritis. The management of rheumatoid arthritis in adults. London: NICE; 2009.Google Scholar
  7. Dixon WG, Abrahamowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suissa S, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis. 2012;71:1128–33.PubMedPubMed CentralView ArticleGoogle Scholar
  8. The Royal Australian College of General Practitioners (RACGP) clinical guidelines for the diagnosis and management of early rheumatoid arthritis. http://www.racgp.org.au/your-practice/guidelines/musculoskeletal/rheumatoidarthritis. Accessed November 2015.
  9. Luqmani R, Hennell S, Estrach C, Birrell F, Bosworth A, Davenport G, et al. British Society for Rheumatology and British health professionals in rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford). 2006;45:1167–9.View ArticleGoogle Scholar
  10. Luqmani R, Hennell S, Estrach C, Basher D, Birrell F, Bosworth A, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford). 2009;48:436–9.View ArticleGoogle Scholar
  11. van der Linden MP, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga TW, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62:3537–46.PubMedView ArticleGoogle Scholar
  12. Henkel G: Glucocorticoid use in rheumatoid arthritis management focus of ongoing debate. In: The Rheumatologist. vol. March 2015: ACR and ARHP; 2015.Google Scholar
  13. Saag KG. Resolved: low-dose glucocorticoids are neither safe nor effective for the long-term treatment of rheumatoid arthritis. Arthr Care Res. 2001;45:468–71.View ArticleGoogle Scholar
  14. Conn DL. Resolved: Low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis. Arthr Care Res. 2001;45:462–7.View ArticleGoogle Scholar
  15. Clinical Practice Research Datalink. UK. http://www.cprd.com/home, Accessed August 2015.
  16. Lawson DH, Sherman V, Hollowell J. The General Practice Research Database. Scientific and Ethical Advisory Group. QJM. 1998;91:445–52.PubMedView ArticleGoogle Scholar
  17. García Rodríguez LA, Pérez GS. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45:419–25.PubMedPubMed CentralView ArticleGoogle Scholar
  18. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69:4–14.PubMedPubMed CentralView ArticleGoogle Scholar
  19. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract. 2010;60:e128–36.PubMedPubMed CentralView ArticleGoogle Scholar
  20. Williams T, van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf. 2012;3:89–99.PubMedPubMed CentralView ArticleGoogle Scholar
  21. Health and Social Care Information Centre-Read Codes. http://systems.hscic.gov.uk/data/uktc/readcodes. Accessed August 2015.
  22. Thomas SL, Edwards CJ, Smeeth L, Cooper C, Hall AJ. How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database? Arthritis Rheum. 2008;59:1314–21.PubMedView ArticleGoogle Scholar
  23. Sokka T, Kautiainen H, Toloza S, Makinen H, Verstappen SM, Lund Hetland M, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis. 2007;66:1491–6.PubMedPubMed CentralView ArticleGoogle Scholar
  24. Buttgereit F, Da Silva JAP, Boers M, Burmester G-R, Cutolo M, Jacobs J, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61:718–22.PubMedPubMed CentralView ArticleGoogle Scholar
  25. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med. 1995;333:142–6.PubMedView ArticleGoogle Scholar
  26. Hickling P, Jacoby RK, Kirwan JR. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol. 1998;37:930–6.PubMedView ArticleGoogle Scholar
  27. Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:3371–80.PubMedView ArticleGoogle Scholar
  28. van Everdingen AA, Jacobs JWG, Siewertsz Van Reesema DR, Bijlsma JWJ. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136:1–12.PubMedView ArticleGoogle Scholar
  29. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964–75.PubMedPubMed CentralView ArticleGoogle Scholar
  30. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55:420–6.PubMedView ArticleGoogle Scholar
  31. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994;96:115–23.PubMedView ArticleGoogle Scholar
  32. Innala L, Berglin E, Moller B, Ljung L, Smedby T, Sodergren A, et al. Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. Arthr Res Ther. 2014;16:R94.View ArticleGoogle Scholar
  33. Villa-Blanco JI, Calvo-Alen J. Elderly onset rheumatoid arthritis: differential diagnosis and choice of first-line and subsequent therapy. Drugs Aging. 2009;26:739–50.PubMedView ArticleGoogle Scholar
  34. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764–70.PubMedView ArticleGoogle Scholar
  35. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol. 1999;26:2562–71.PubMedGoogle Scholar
  36. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol. 2003;21:S154–157.PubMedGoogle Scholar
  37. Naumann L, Huscher D, Detert J, Spengler M, Burmester GR, Buttgereit F. Anti-tumour necrosis factor {alpha} therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment. Ann Rheum Dis. 2009;68:1934–6.PubMedView ArticleGoogle Scholar
  38. Seror R, Dougados M, Gossec L. Glucocorticoid sparing effect of tumour necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice. Clin Exp Rheumatol. 2009;27:807–13.PubMedGoogle Scholar
  39. Nilsson AC, Christensen AF, Junker P, Lindegaard HM. Tumour necrosis factor-alpha inhibitors are glucocorticoid-sparing in rheumatoid arthritis. Dan Med Bull. 2011;58:A4257.PubMedGoogle Scholar
  40. Fortunet C, Pers YM, Lambert J, Godfrin-Valnet M, Constant E, Devilliers H, et al. Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. Rheumatology (Oxford). 2015;54:672–7.View ArticleGoogle Scholar

Copyright

© Black et al. 2015

Advertisement